Phase 2 N=125 NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
Diabetic Macular Edema
Primary: Mean Change in Optical Coherence Tomography Measure Retinal Volume, mm3 — 0.02; -0.03 mm3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Phase 2 N=20 Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease…
Phase 2 N=127 Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Complicated Urinary Tract Infection
Primary: Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population — 83.1; 76.3 percentage of patients
Phase 2 N=87 A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Prostatic Neoplasms
Primary: Progression Free Rate (PFR) at 12 Weeks — 25.9; 0.0; 0.0; NA percentage of participants — p=0.0577
Phase 2 N=31 Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Cancer · Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer
Primary: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 3.6 percentage of evalubale patients
Phase 2 N=12 Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells
Osteoarthritis, Knee · Knee Degenerative Disease · Knee Osteoarthritis
Primary: Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee. — 46.9; 25.1; 24.8; 15.4 units on a scale
Phase 2 N=159 Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Asthma
Primary: Change From Baseline in Morning (Ante Meridiem) Peak Expiratory Flow Rate (AM PEFR) at Day 112 - Stage 1 — 286.4; 297.6; 343.5; 291.5 liter per minute (L/min)
Phase 2 N=52 Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Stage IV Pancreatic Cancer
Primary: Objective Response (OR = CR or PR) as Determined by the RECIST Criteria — 0; 1 participants
Phase 2 N=9 Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Carcinoma, Renal Cell · Kidney Disease · Kidney Cancer
Primary: Time-to-progression (TTP) — 5.3 months
Phase 2 N=13 Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
Major Depressive Disorder
Primary: Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating…
Phase 2 N=46 Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Leukemia · Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Regimen Related Toxicities — 56; 70; 4; 10 toxicities
Phase 2 N=10 A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration Day 3 — 2103; 2112; 2366; 2657 ng/ml
Phase 2 N=20 Trial Of Double Umbilical Cord Blood Transplantation
Hematological Malignancies
Primary: Percentage of Participants Alive at 1 Year After Transplant — 40 percentage of participants
Phase 2 N=341 Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline at Week 4 in ADHD Symptoms Measured With the ADHD Rating Scale Version IV With Adult Prompts (ADHD RS IV) — -12.38; -13.88; -9.7 units on a scale…